Роль олмесартана в клинической практике
- Авторы: Барышникова Г.А1, Чорбинская С.А1, Степанова И.И1, Чупрова Н.В1
-
Учреждения:
- ФГБУ Учебно-научный медицинский центр Управления делами Президента РФ, Москва
- Выпуск: Том 15, № 1 (2013)
- Страницы: 18-22
- Раздел: Статьи
- URL: https://ogarev-online.ru/2075-1753/article/view/93724
- ID: 93724
Цитировать
Полный текст
Аннотация
Ключевые слова
Полный текст
Открыть статью на сайте журналаОб авторах
Г. А Барышникова
ФГБУ Учебно-научный медицинский центр Управления делами Президента РФ, МоскваКафедра семейной медицины
С. А Чорбинская
ФГБУ Учебно-научный медицинский центр Управления делами Президента РФ, МоскваКафедра семейной медицины
И. И Степанова
ФГБУ Учебно-научный медицинский центр Управления делами Президента РФ, МоскваКафедра семейной медицины
Н. В Чупрова
ФГБУ Учебно-научный медицинский центр Управления делами Президента РФ, МоскваКафедра семейной медицины
Список литературы
- Munzel T, Sinning C, Post Fю et al. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 2008; 40 (3): 180–96, 653–8.
- Pahkala K, Heinonen O.J., Lagstrom H. et al. Vascular endothelial function and leisure - time physical activity in adolescents. Circulation 2008; 118 (23): 2353–9.
- Brunner H.R. (2002) The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens 16 (Suppl. 2): S13–16.
- Puchler K, Laies P, Stumpe K. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens Suppl 2001; 19: S41–S48.
- Oparil S, Williams D, Chrysant S.G. et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283–91.
- Norwood D, Branch E, Smith B et al. Olmesartan medoxomil for hypertension: a clinical review. Drug Forecast 2002; 27: 611–8.
- Chrysant S.G., Marbury T.C., Robinson T.D. The antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild - to - moderate hypertension. J Hum Hypertens 2003; 17: 425–32.
- Chrysant S.G., Marbury T.C., Silfani T.N. Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. Blood Press Monit 2006; 11: 135–41.
- Рекомендации РМОАГ/ВНОК по диагностике и лечению артериальной гипертонии (4-й пересмотр), 2010.
- Barrios V, Boccanelli A, Ewald S. et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Clin Drug Investig 2007; 27: 545–58.
- Chrysant S.G., Melino M. et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double - blind, placebo - controlled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30: 587–604.
- Kereiakes D.J., Neutel J.M., Punzi H.A. et al. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am J Cardiovasc Drugs 2007; 7: 361–72.
- Neutel J.M., Smith D.H., Silfani T.N. et al. Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. J Hum Hypertens 2006; 20: 255–62.
- Neutel J.M., Smith D.H., Weber M.A. et al. Use of an olmesartan medoxomil - based treatment algorithm for hypertension control. J Clin Hypertens (Greenwich) 2004; 6: 168–74.
- Naya M, Tsukamoto T, Morita K. et al. Olmesartan, but not amlodipine, improves endothelium - dependent coronary dilation in hypertensive patients. J Am Coll Cardiol 2007; 50 (12): 1144–9.
- Smith R.D., Yokoyama H, Averill D.B. et al. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics. Am J Cardiovasc Drugs 2006; 6 (5): 335–42.
- Stumpe K, Agabiti-Rosei E, Zielinski T. et al. Carotid intima - media thickness and plaque volume changes following 2-year angiotensin II receptor blockade. The multicentre olmesartan atherosclerosis regression evaluation (MORE) study. Ther Adv Cardiovasc Dis 2007; 1 (2): 97–106.
- Hirohata A, Yamamoto K, Miyoshi T et al. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol 2010; 55 (10): 976–82.
- Ikeda H, Hamamoto Y, Honjo S et al. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes. Diabetes Res Clin Pract 2009; 83 (1): 117–8.
- Haller H, Ito S, Izzo J.L. et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907–17.
- Чазова И.Е., Фомин В.В. Управление кардиоренальным синдромом: возможности блокаторов рецепторов ангиотензина II. Фарматека. 2011; 15: 10–4.
- Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinfl ammation. Circulation 2004; 110 (9): 1103–7.
- Brunner H.R. Clinical efficacy and tolerability of olmesartan. Clin Ther 2004; 26 (Suppl. A): A28–A32.
- Oparil S, Williams D, Chrysant S.G. et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283–91.
- Brunner H.R., Stumpe K.O., Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexitil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003; 23: 419–30.
- Zanorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J et al. Serum concentration of visfatin in obese women. Metabolism 2007; 56: 1131–4.
- De Luis D.A., Conde R, Gonzalez Sagrado M. Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women. Eur Rev Med Pharmacol Sci 2010; 14: 759–63.
- Fabia M.J., Abdilla N, Oltra R. et al. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007; 25 (7): 1327–36.
Дополнительные файлы
